Protocolo diagnóstico y terapéutico de la enfermedad ósea tumoral metastásica

  1. Nalda Ariza, I. 1
  2. Bernier García, L. 1
  3. Peñas Pita da Veiga, M. 1
  4. Cassinello Espinosa, J. 1
  1. 1 Unidad de Oncología Médica, Hospital Universitario de Guadalajara, Guadalajara, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2021

Título del ejemplar: Enfermedades oncológicas (III) Tumores genitourinarios

Serie: 13

Número: 26

Páginas: 1473-1476

Tipo: Artículo

DOI: 10.1016/J.MED.2021.02.015 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Objetivos de desarrollo sostenible

Resumen

The bone is the most frequent localization of the solid tumor metastases that develop in 65%-75% of patients with advanced cancer. They represent one of the main potential threats to patients due to the comorbidity and deterioration in quality of life that they cause. Skeletal-related events (SRE) are complications that arise from this bone disease and include pathological fractures, need for surgery or radiotherapy, and spinal cord compression. These lesions can be osteoblastic or osteolytic in nature and their diagnosis must be based on both clinical suspicion and diagnostic imaging tests such as a bone gammagraphy, a positron emission tomography scan combined with a computed tomography scan, or magnetic resonance imaging. Treatment of bone metastases must be multidisciplinary and systemic, with bisphosphonates or denosuman, as well as local, with radiotherapy or surgery. The importance of adequate treatment of the underlying tumor disease and possible associated pain is essential.

€ Ver financiación

Información de financiación

Funding. This work was supported by U.S. Department of Veterans Affairs Career Development Awards (CDA-2: RX002928 to R.S.A. and CDA-2: RX002342 to A.J.F.) and Senior Research Career Scientist Award IK6-RX003134 (to M.T.P.), Center for Scientific Review grant P30-EY-006360, Research to Prevent Blindness (Unrestricted Department Grant to the Department of Ophthalmology, Emory University [to A.M.H.]), and U.S. Department of Veterans Affairs Rehabilitation Research & Development Service (Merit Award I01-RX2615 to M.T.P.). Duality of Interest. No potential conflicts of interest relevant to this article were reported. Author Contributions. C.T.M. collected and analyzed data and wrote the manuscript. K.C.C. collected and analyzed data and edited the manuscript. R.S.A. collected data and edited the manuscript. K.L.B. collected data and edited the manuscript. L.M.M. collected data. A.J.F. analyzed data and edited the manuscript. A.Y.M. assisted with recruitment and edited the manuscript. D.E.O. assisted with recruitment and edited the manuscript. P.M.T. assisted with recruitment and edited the manuscript. P.M.I. reviewed and edited the manuscript. A.M.H. reviewed and edited the manuscript. M.T.P. managed the project, analyzed data, and edited the manuscript. M.T.P. is the guarantor of this work and, as such, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Prior Presentation. Parts of this study were presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology, Vancouver, British Columbia, Canada, 28 April–2 May 2019.

Financiadores

Referencias bibliográficas

  • Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Fleisch H, et al. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol. 1998;16(12):3890-9. doi:10.1200/JCO.1998.16.12.3890
  • von Moos R, Costa L, González Suárez E, Terpos E, Niepel D, Body JJ. Management of bone health in solid tumours: from bisphosphonates to a monoclonal antibody. Cancer Treat Rev. 2019;76:57e67
  • Cassinello Espinosa J, González del Alba Baamonde A, Rivera Herrero F, et al. SEOM guidelines for the treatment of bone metastases from solid tumours. Clin Transl Oncol. 2012 (14):505-11. doi: 10.1007/s12094-012-0832-0
  • Dennis ER, Jia X, Mezheritskiy IS, Stephenson RD, Schoder H, Fox JJ, et al. Bone scan index: a quantitative treatment response biomarker for castration resistant metastatic prostate cancer. J Clin Oncol. 2012;30:519e524.
  • Manohar PR, Rather TA, Khan SH, Malik D. Skeletal metastases presenting as superscan on technetium 99m methylene diphosphonate whole body bone scintigraphy in different type of cancers: a 5-year retropro-spective study. World J Nucl Med. 2017;16(1):39-44. doi:10.4103/1450-1147.181153
  • Rich SE, Chow R, Raman S, Liang Zeng K, Lutz S, Lam H, et al. Update of the systematic review of palliative radiation therapy fractionation for bone metastases. Radiother Oncol. 2018;126:547e557.
  • Hoskin PJ, Hopkins K, Misra V, Holt T, McMenemin R, Dubois D, et al. Effect of single fraction vs multifraction radiotherapy on ambulatory status among patients with spinal canal compression from metastatic cancer: the SCORAD randomized clinical trial. JAMA. 2019;322(21):2084e2094.
  • D’Oronzo S, Coleman R, Brown J, Silvestris F. Metastatic bone disease: pathogenesis and therapeutic options: up-date on bone metastasis management. J Bone Oncol. 2019;15:004.
  • Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cáncer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005; 23:8580-7.
  • Fizazi K, Carducci MA, Smith MR, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledrónic acid for the treatment of bone metastases in men with castration resistant prostate cancer: a randomized, doubled blind study. Lancet. 2011;377:813-22.✔11. Ford J, Jones R, Elders A, Stewart F, Todd R, Mowatt G. Denosumab in patients with cancer and skeletal metastases: A systematic review and meta-analysis. Eur J Cancer. 2013;49(2):416-30.
  • Peddi P, López Olivo M, Pratt GF, Suárez Almazor ME. Denosumab for the treatment of bone metastases secondary to solid tumors: systematic review and network meta-analysis. Cancer Treat Rev. 2013;39:97-104.
  • Sun L, Yu S. Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases: a systematic review and meta-analysis. Am J Clin Oncol. 2013;36(4):399-403.
  • Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29:1125-32
Fuente de los datos: Dialnet